• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound.采用灰黄霉素作为模型化合物,通过不同的中试规模工艺生成无定形固体分散体的体外和体内评价。
AAPS J. 2013 Apr;15(2):608-17. doi: 10.1208/s12248-013-9469-3. Epub 2013 Mar 2.
2
A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine.喷雾干燥法和热熔挤出法对含非洛地平无定形固体分散体性质影响的比较研究。
J Pharm Pharmacol. 2014 Feb;66(2):275-84. doi: 10.1111/jphp.12099. Epub 2013 Jul 10.
3
Effect of drug-polymer interactions on the aqueous solubility of milled solid dispersions.药物-聚合物相互作用对研磨固体分散体水溶解度的影响。
Int J Pharm. 2013 Mar 25;446(1-2):100-5. doi: 10.1016/j.ijpharm.2013.02.009. Epub 2013 Feb 11.
4
Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS.评价灰黄霉素二元和三元固体分散体与 HPMCAS 的效果。
AAPS PharmSciTech. 2009;10(4):1172-7. doi: 10.1208/s12249-009-9319-x. Epub 2009 Oct 20.
5
Investigation of griseofulvin and hydroxypropylmethyl cellulose acetate succinate miscibility in ball milled solid dispersions.球磨固体分散体中灰黄霉素和羟丙甲纤维素醋酸琥珀酸酯的混溶性研究。
Int J Pharm. 2013 Feb 25;443(1-2):95-102. doi: 10.1016/j.ijpharm.2012.12.045. Epub 2013 Jan 6.
6
The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.无定形形式作为亲脂性化合物口服药物传递实践的双重优势:增加表观溶解度和药物通过肠膜的通量。
AAPS J. 2013 Apr;15(2):347-53. doi: 10.1208/s12248-012-9445-3. Epub 2012 Dec 15.
7
Atypical effects of incorporated surfactants on stability and dissolution properties of amorphous polymeric dispersions.掺入的表面活性剂对无定形聚合物分散体稳定性和溶解性能的非典型影响。
J Pharm Pharmacol. 2016 Nov;68(11):1373-1383. doi: 10.1111/jphp.12645. Epub 2016 Oct 2.
8
Preparation and evaluation of high dispersion stable nanocrystal formulation of poorly water-soluble compounds by using povacoat.使用泊洛沙姆包衣制备和评价难溶性化合物的高分散稳定纳米晶制剂
J Pharm Sci. 2014 Nov;103(11):3772-3781. doi: 10.1002/jps.24147. Epub 2014 Sep 10.
9
Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery.采用 96 孔板真空干燥系统评价无定形固体分散体药物传递中的载药量和聚合物。
AAPS PharmSciTech. 2012 Jun;13(2):713-22. doi: 10.1208/s12249-012-9795-2. Epub 2012 May 5.
10
Site specific solubility improvement using solid dispersions of HPMC-AS/HPC SSL--mixtures.使用羟丙甲纤维素邻苯二甲酸酯/羟丙基纤维素固体分散体混合物进行特定部位的溶解度改善。
Eur J Pharm Biopharm. 2014 Jul;87(2):264-70. doi: 10.1016/j.ejpb.2014.03.018. Epub 2014 Apr 21.

引用本文的文献

1
Optimization of Spray-Drying Parameters for Formulation Development at Preclinical Scale.优化喷雾干燥参数,以开发临床前规模的配方。
AAPS PharmSciTech. 2021 Dec 20;23(1):28. doi: 10.1208/s12249-021-02160-1.
2
Hierarchical Particle Approach for Co-Precipitated Amorphous Solid Dispersions for Use in Preclinical In Vivo Studies.用于临床前体内研究的共沉淀无定形固体分散体的分层粒子方法。
Pharmaceutics. 2021 Jul 7;13(7):1034. doi: 10.3390/pharmaceutics13071034.
3
Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.灰黄霉素环糊精基纳米海绵作为儿科口服液剂型的制剂与评价,以提高生物利用度并掩盖苦味。
Saudi Pharm J. 2020 Mar;28(3):349-361. doi: 10.1016/j.jsps.2020.01.016. Epub 2020 Feb 3.
4
Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy.喷雾干燥 OZ439 纳米颗粒,形成稳定的、水分散性的粉末,用于口服疟疾治疗。
J Transl Med. 2019 Mar 22;17(1):97. doi: 10.1186/s12967-019-1849-8.
5
Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions.固体核磁共振研究吲哚美辛-乙基纤维素 E 无定形固体分散体中药物-赋形剂相互作用和相行为。
Pharm Res. 2018 Feb 20;35(3):65. doi: 10.1007/s11095-018-2364-y.

本文引用的文献

1
Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery.采用 96 孔板真空干燥系统评价无定形固体分散体药物传递中的载药量和聚合物。
AAPS PharmSciTech. 2012 Jun;13(2):713-22. doi: 10.1208/s12249-012-9795-2. Epub 2012 May 5.
2
Assessing the performance of amorphous solid dispersions.评估无定形固体分散体的性能。
J Pharm Sci. 2012 Apr;101(4):1355-77. doi: 10.1002/jps.23031. Epub 2011 Dec 27.
3
A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.法尼醇 X 受体激动剂 GW4064 在仓鼠和食蟹猴中的配方支持的临床前疗效评估。
J Pharm Sci. 2011 Nov;100(11):4722-33. doi: 10.1002/jps.22664. Epub 2011 Jun 9.
4
Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.无定形药物的溶解度优势:二、定量热力学关系在结构多样的难溶性药物增溶预测中的应用。
Pharm Res. 2010 Dec;27(12):2704-14. doi: 10.1007/s11095-010-0269-5. Epub 2010 Sep 22.
5
Analysis of amorphous solid dispersions using 2D solid-state NMR and (1)H T(1) relaxation measurements.使用二维固态 NMR 和 (1)H T(1) 弛豫测量分析无定形固体分散体。
Mol Pharm. 2010 Oct 4;7(5):1667-91. doi: 10.1021/mp100205g. Epub 2010 Aug 3.
6
Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?单一 Tg 是否能可靠地指示无定形固体分散体的均一性?
Int J Pharm. 2010 Aug 16;395(1-2):232-5. doi: 10.1016/j.ijpharm.2010.05.033. Epub 2010 May 24.
7
Physical stability studies of miscible amorphous solid dispersions.可混溶性无定形固体分散体的物理稳定性研究。
J Pharm Sci. 2010 Sep;99(9):4005-12. doi: 10.1002/jps.22247.
8
Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS.评价灰黄霉素二元和三元固体分散体与 HPMCAS 的效果。
AAPS PharmSciTech. 2009;10(4):1172-7. doi: 10.1208/s12249-009-9319-x. Epub 2009 Oct 20.
9
Evaluation of drug-polymer miscibility in amorphous solid dispersion systems.评价无定形固体分散体系统中药物-聚合物的混合性。
Pharm Res. 2009 Nov;26(11):2523-34. doi: 10.1007/s11095-009-9970-7. Epub 2009 Sep 22.
10
Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.无定形药物的溶解度优势:I. 热力学分析。
J Pharm Sci. 2010 Mar;99(3):1254-64. doi: 10.1002/jps.21903.

采用灰黄霉素作为模型化合物,通过不同的中试规模工艺生成无定形固体分散体的体外和体内评价。

In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound.

机构信息

Global Research and Development, DMPK, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

出版信息

AAPS J. 2013 Apr;15(2):608-17. doi: 10.1208/s12248-013-9469-3. Epub 2013 Mar 2.

DOI:10.1208/s12248-013-9469-3
PMID:23456436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3675757/
Abstract

Drug polymer-based amorphous solid dispersions (ASD) are widely used in the pharmaceutical industry to improve bioavailability for poorly water-soluble compounds. Spray-drying is the most common process involved in the manufacturing of ASD material. However, spray-drying involves a high investment of material quantity and time. Lower investment manufacturing processes such as fast evaporation and freeze-drying (lyophilization) have been developed to manufacture ASD at the bench level. The general belief is that the overall performance of ASD material is thermodynamically driven and should be independent of the manufacturing process. However, no formal comparison has been made to assess the in vivo performance of material generated by different processes. This study compares the in vitro and in vivo properties of ASD material generated by fast evaporation, lyophilization, and spray-drying methods using griseofulvin as a model compound and hydroxypropyl methylcellulose acetate succinate as the polymer matrix. Our data suggest that despite minor differences in the formulation release properties and stability of the ASD materials, the overall exposure is comparable between the three manufacturing processes under the conditions examined. These results suggest that fast evaporation and lyophilization may be suitable to generate ASD material for oral evaluation. However, caution should be exercised since the general applicability of the present findings will need to be further evaluated.

摘要

药物聚合物无定形固体分散体(ASD)广泛用于制药行业,以提高水溶性差的化合物的生物利用度。喷雾干燥是制造 ASD 材料最常用的工艺。然而,喷雾干燥涉及大量的材料投入和时间。已经开发了较低投资的制造工艺,如快速蒸发和冷冻干燥(冻干),以在台架水平上制造 ASD。一般认为,ASD 材料的整体性能是由热力学驱动的,应该与制造工艺无关。然而,尚未进行正式比较以评估不同工艺产生的材料的体内性能。本研究使用灰黄霉素作为模型化合物和醋酸羟丙甲纤维素琥珀酸酯作为聚合物基质,比较了快速蒸发、冻干和喷雾干燥方法制备的 ASD 材料的体外和体内性质。我们的数据表明,尽管 ASD 材料的配方释放特性和稳定性存在微小差异,但在研究条件下,三种制造工艺的整体暴露情况相当。这些结果表明,快速蒸发和冻干可能适合用于口服评价的 ASD 材料的生成。然而,需要谨慎,因为需要进一步评估目前研究结果的普遍适用性。